Myelodysplastic Syndromes
The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
Abstract
MDS are clonal hematopoietic disorders involving morphologic defects and peripheral-blood cytopenias, with a risk of progression to acute myeloid leukemia. Except for del(5q) MDS, which is responsive to lenalidomide, these disorders are largely managed with supportive care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119
Self-citationAge-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Proposals for the classification of the myelodysplastic syndromes
Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb08475.x · Cited by 3,627
Pan-cancer analysis of whole genomes
The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, Aaltonen, L. A., Abascal, F., Abeshouse, A., Aburatani, H., Adams, D. J., Agrawal, N., Ahn, K. S., Ahn, S.-M., Aikata, H., et al. (2020) · Nature · doi:10.1038/s41586-020-1969-6 · Cited by 3,064
Self-citationRevised International Prognostic Scoring System for Myelodysplastic Syndromes
Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Solé, F., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., et al. (2012) · Blood · doi:10.1182/blood-2012-03-420489 · Cited by 2,844
Self-citationFigueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70003-8 · Cited by 2,663
Frequent pathway mutations of splicing machinery in myelodysplasia
Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., et al. (2011) · Nature · doi:10.1038/nature10496 · Cited by 2,029
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
Steensma, D. P., Bejar, R., Jaiswal, S., Lindsley, R. C., Sekeres, M. A., Hasserjian, R. P., & Ebert, B. L. (2015) · Blood · doi:10.1182/blood-2015-03-631747 · Cited by 1,971
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Papaemmanuil, E., Gerstung, M., Malcovati, L., Tauro, S., Gundem, G., Van Loo, P., Yoon, C. J., Ellis, P., Wedge, D. C., Pellagatti, A., et al. (2013) · Blood · doi:10.1182/blood-2013-08-518886 · Cited by 1,832
Self-citationDiNardo, C. D., Pratz, K., Pullarkat, V., Jonas, B. A., Arellano, M., Becker, P. S., Frankfurt, O., Konopleva, M., Wei, A. H., Kantarjian, H. M., et al. (2019) · Blood · doi:10.1182/blood-2018-08-868752 · Cited by 1,825
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G., Kantarjian, H., Raza, A., Levine, R. L., Neuberg, D., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013343 · Cited by 1,627
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
Haferlach, T., Nagata, Y., Grossmann, V, Okuno, Y., Bacher, U., Nagae, G., Schnittger, S., Sanada, M., Kon, A., Alpermann, T., et al. (2014) · Leukemia · doi:10.1038/leu.2013.336 · Cited by 1,532
Ford, I., & Norrie, J. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1510059 · Cited by 1,405
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation
Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M. E., Vasanthakumar, A., Patel, J., Zhao, X., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.001 · Cited by 1,339
Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts
Papaemmanuil, E., Cazzola, M., Boultwood, J., Malcovati, L., Vyas, P., Bowen, D., Pellagatti, A., Wainscoat, J. S., Hellstrom-Lindberg, E., Gambacorti-Passerini, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103283 · Cited by 1,222
Self-citationInactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Ernst, T., Chase, A. J., Score, J., Hidalgo-Curtis, C. E., Bryant, C., Jones, A. V., Waghorn, K., Zoi, K., Ross, F. M., Reiter, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.621 · Cited by 1,139
Lancet, J. E., Uy, G. L., Cortes, J. E., Newell, L. F., Lin, T. L., Ritchie, E. K., Stuart, R. K., Strickland, S. A., Hogge, D., Solomon, S. R., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6112 · Cited by 1,025
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations
Lindsley, R. C., Mar, B. G., Mazzola, E., Grauman, P. V., Shareef, S., Allen, S. L., Pigneux, A., Wetzler, M., Stuart, R. K., Erba, H. P., et al. (2015) · Blood · doi:10.1182/blood-2014-11-610543 · Cited by 991
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen
Ebert, B. L., Pretz, J., Bosco, J., Chang, C. Y., Tamayo, P., Galili, N., Raza, A., Root, D. E., Attar, E., Ellis, S. R., et al. (2008) · Nature · doi:10.1038/nature06494 · Cited by 928
Malcovati, L., Porta, M. G. D., Pascutto, C., Invernizzi, R., Boni, M., Travaglino, E., Passamonti, F., Arcaini, L., Maffioli, M., Bernasconi, P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.7038 · Cited by 865
Self-citationLenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
Krönke, J., Fink, E. C., Hollenbach, P. W., MacBeth, K. J., Hurst, S. N., Udeshi, N. D., Chamberlain, P. P., Mani, D. R., Man, H. W., Gandhi, A. K., et al. (2015) · Nature · doi:10.1038/nature14610 · Cited by 863
Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation
Lindsley, R. C., Saber, W., Mar, B. G., Redd, R., Wang, T., Haagenson, M. D., Grauman, P. V., Hu, Z.-H., Spellman, S. R., Lee, S. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611604 · Cited by 776
Clonal Architecture of Secondary Acute Myeloid Leukemia
Walter, M. J., Shen, D., Ding, L., Shao, J., Koboldt, D. C., Chen, K., Larson, D. E., McLellan, M. D., Dooling, D., Abbott, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106968 · Cited by 775
Malcovati, L., Hellström-Lindberg, E., Bowen, D., Adès, L., Cermak, J., del Cañizo, C., Della Porta, M. G., Fenaux, P., Gattermann, N., Germing, U., et al. (2013) · Blood · doi:10.1182/blood-2013-03-492884 · Cited by 669
Self-citationBernard, E., Nannya, Y., Hasserjian, R. P., Devlin, S. M., Tuechler, H., Medina-Martinez, J. S., Yoshizato, T., Shiozawa, Y., Saiki, R., Malcovati, L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1008-z · Cited by 648
Self-citationRecurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes
Graubert, T. A., Shen, D., Ding, L., Okeyo-Owuor, T., Lunn, C. L., Shao, J., Krysiak, K., Harris, C. C., Koboldt, D. C., Larson, D. E., et al. (2012) · Nature Genetics · doi:10.1038/ng.1031 · Cited by 580
Identification of miR-145 and miR-146a as mediators of the 5q– syndrome phenotype
Starczynowski, D. T., Kuchenbauer, F., Argiropoulos, B., Sung, S., Morin, R., Muranyi, A., Hirst, M., Hogge, D., Marra, M., Wells, R. A., et al. (2010) · Nature Medicine · doi:10.1038/nm.2054 · Cited by 577
SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition
Kim, E., Ilagan, J. O., Liang, Y., Daubner, G. M., Lee, S. C.-W., Ramakrishnan, A., Li, Y., Chung, Y. R., Micol, J.-B., Murphy, M. E., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.04.006 · Cited by 575
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
Fenaux, P., Platzbecker, U., Mufti, G. J., Garcia-Manero, G., Buckstein, R., Santini, V., Díez-Campelo, M., Finelli, C., Cazzola, M., Ilhan, O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1908892 · Cited by 550
Self-citationFenaux, P., Giagounidis, A., Selleslag, D., Beyne-Rauzy, O., Mufti, G., Mittelman, M., Muus, P., te Boekhorst, P., Sanz, G., del Cañizo, C., et al. (2011) · Blood · doi:10.1182/blood-2011-01-330126 · Cited by 486
Self-citationClinical significance of somatic mutation in unexplained blood cytopenia
Malcovati, L., Gallì, A., Travaglino, E., Ambaglio, I., Rizzo, E., Molteni, E., Elena, C., Ferretti, V. V., Catricalà, S., Bono, E., et al. (2017) · Blood · doi:10.1182/blood-2017-01-763425 · Cited by 478
Self-citationTP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression
Jädersten, M., Saft, L., Smith, A., Kulasekararaj, A., Pomplun, S., Göhring, G., Hedlund, A., Hast, R., Schlegelberger, B., Porwit, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8576 · Cited by 463
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts
Malcovati, L., Karimi, M., Papaemmanuil, E., Ambaglio, I., Jädersten, M., Jansson, M., Elena, C., Gallì, A., Walldin, G., Della Porta, M. G., et al. (2015) · Blood · doi:10.1182/blood-2015-03-633537 · Cited by 434
Self-citationDynamics of clonal evolution in myelodysplastic syndromes
Makishima, H., Yoshizato, T., Yoshida, K., Sekeres, M. A., Radivoyevitch, T., Suzuki, H., Przychodzen, B., Nagata, Y., Meggendorfer, M., Sanada, M., et al. (2017) · Nature Genetics · doi:10.1038/ng.3742 · Cited by 422
Buscarlet, M., Provost, S., Zada, Y. F., Barhdadi, A., Bourgoin, V., Lépine, G., Mollica, L., Szuber, N., Dubé, M.-P., & Busque, L. (2017) · Blood · doi:10.1182/blood-2017-04-777029 · Cited by 383
Obeng, E. A., Chappell, R. J., Seiler, M., Chen, M. C., Campagna, D. R., Schmidt, P. J., Schneider, R. K., Lord, A. M., Wang, L., Gambe, R. G., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.08.006 · Cited by 380
de Witte, T., Bowen, D., Robin, M., Malcovati, L., Niederwieser, D., Yakoub-Agha, I., Mufti, G. J., Fenaux, P., Sanz, G., Martino, R., et al. (2017) · Blood · doi:10.1182/blood-2016-06-724500 · Cited by 379
Clinical and Therapeutic Implications of Cancer Stem Cells
Clarke, M. F. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1804280 · Cited by 355
A landscape of germ line mutations in a cohort of inherited bone marrow failure patients
Bluteau, O., Sebert, M., Leblanc, T., Peffault de Latour, R., Quentin, S., Lainey, E., Hernandez, L., Dalle, J.-H., Sicre de Fontbrune, F., Lengline, E., et al. (2018) · Blood · doi:10.1182/blood-2017-09-806489 · Cited by 355
The genetic basis of myelodysplasia and its clinical relevance
Cazzola, M., Della Porta, M. G., & Malcovati, L. (2013) · Blood · doi:10.1182/blood-2013-09-381665 · Cited by 346
Self-citationMyelodysplastic Syndromes — Coping with Ineffective Hematopoiesis
Cazzola, M., & Malcovati, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmp048266 · Cited by 343
Self-citationStein, E. M., DiNardo, C. D., Fathi, A. T., Pollyea, D. A., Stone, R. M., Altman, J. K., Roboz, G. J., Patel, M. R., Collins, R., Flinn, I. W., et al. (2019) · Blood · doi:10.1182/blood-2018-08-869008 · Cited by 331
Myelodysplastic Syndromes Are Propagated by Rare and Distinct Human Cancer Stem Cells In Vivo
Woll, P. S., Kjällquist, U., Chowdhury, O., Doolittle, H., Wedge, D. C., Thongjuea, S., Erlandsson, R., Ngara, M., Anderson, K., Deng, Q., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.036 · Cited by 320
Self-citationKwok, B., Hall, J. M., Witte, J. S., Xu, Y., Reddy, P., Lin, K., Flamholz, R., Dabbas, B., Yung, A., Al-Hafidh, J., et al. (2015) · Blood · doi:10.1182/blood-2015-08-667063 · Cited by 317
Classification, Ontology, and Precision Medicine
Haendel, M. A., Chute, C. G., & Robinson, P. N. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1615014 · Cited by 317
Chen, L., Chen, J.-Y., Huang, Y.-J., Gu, Y., Qiu, J., Qian, H., Shao, C., Zhang, X., Hu, J., Li, H., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2017.12.029 · Cited by 299
Malcovati, L., Stevenson, K., Papaemmanuil, E., Neuberg, D., Bejar, R., Boultwood, J., Bowen, D. T., Campbell, P. J., Ebert, B. L., Fenaux, P., et al. (2020) · Blood · doi:10.1182/blood.2020004850 · Cited by 297
Self-citationMutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo
Shirai, C. L., Ley, J. N., White, B. S., Kim, S., Tibbitts, J., Shao, J., Ndonwi, M., Wadugu, B., Duncavage, E. J., Okeyo-Owuor, T., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.04.008 · Cited by 287
Della Porta, M. G., Malcovati, L., Boveri, E., Travaglino, E., Pietra, D., Pascutto, C., Passamonti, F., Invernizzi, R., Castello, A., Magrini, U., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.2246 · Cited by 254
Self-citationDella Porta, M. G., Gallì, A., Bacigalupo, A., Zibellini, S., Bernardi, M., Rizzo, E., Allione, B., van Lint, M. T., Pioltelli, P., Marenco, P., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3616 · Cited by 254
Self-citationPersistent Malignant Stem Cells in del(5q) Myelodysplasia in Remission
Tehranchi, R., Woll, P. S., Anderson, K., Buza-Vidas, N., Mizukami, T., Mead, A. J., Åstrand-Grundström, I., Strömbeck, B., Horvat, A., Ferry, H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0912228 · Cited by 253
Smith, M. A., Choudhary, G. S., Pellagatti, A., Choi, K., Bolanos, L. C., Bhagat, T. D., Gordon-Mitchell, S., Von Ahrens, D., Pradhan, K., Steeples, V., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0314-5 · Cited by 247
Pellagatti, A., Armstrong, R. N., Steeples, V., Sharma, E., Repapi, E., Singh, S., Sanchi, A., Radujkovic, A., Horn, P., Dolatshad, H., et al. (2018) · Blood · doi:10.1182/blood-2018-04-843771 · Cited by 244
Self-citationDella Porta, M. G., Malcovati, L., Strupp, C., Ambaglio, I., Kuendgen, A., Zipperer, E., Travaglino, E., Invernizzi, R., Pascutto, C., Lazzarino, M., et al. (2011) · Haematologica · doi:10.3324/haematol.2010.033506 · Cited by 243
Self-citationRps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9
Schneider, R. K., Schenone, M., Ferreira, M. V., Kramann, R., Joyce, C. E., Hartigan, C., Beier, F., Brümmendorf, T. H., Germing, U., Platzbecker, U., et al. (2016) · Nature Medicine · doi:10.1038/nm.4047 · Cited by 240
Sekeres, M. A., Othus, M., List, A. F., Odenike, O., Stone, R. M., Gore, S. D., Litzow, M. R., Buckstein, R., Fang, M., Roulston, D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.2510 · Cited by 237
Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level
Chen, J., Kao, Y.-R., Sun, D., Todorova, T. I., Reynolds, D., Narayanagari, S.-R., Montagna, C., Will, B., Verma, A., & Steidl, U. (2019) · Nature Medicine · doi:10.1038/s41591-018-0267-4 · Cited by 226
Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis
Yoshimi, A., Lin, K.-T., Wiseman, D. H., Rahman, M. A., Pastore, A., Wang, B., Lee, S. C.-W., Micol, J.-B., Zhang, X. J., de Botton, S., et al. (2019) · Nature · doi:10.1038/s41586-019-1618-0 · Cited by 220
Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations
Lee, S. C.-W., North, K., Kim, E., Jang, E., Obeng, E., Lu, S. X., Liu, B., Inoue, D., Yoshimi, A., Ki, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.07.003 · Cited by 219
Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia
Churpek, J. E., Pyrtel, K., Kanchi, K.-L., Shao, J., Koboldt, D., Miller, C. A., Shen, D., Fulton, R., O’Laughlin, M., Fronick, C., et al. (2015) · Blood · doi:10.1182/blood-2015-04-641100 · Cited by 216
Santini, V., Almeida, A., Giagounidis, A., Gröpper, S., Jonasova, A., Vey, N., Mufti, G. J., Buckstein, R., Mittelman, M., Platzbecker, U., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.0118 · Cited by 215
Germline DDX41 mutations define a significant entity within adult MDS/AML patients
Sébert, M., Passet, M., Raimbault, A., Rahmé, R., Raffoux, E., Sicre de Fontbrune, F., Cerrano, M., Quentin, S., Vasquez, N., Da Costa, M., et al. (2019) · Blood · doi:10.1182/blood.2019000909 · Cited by 211
The genomic landscape of pediatric myelodysplastic syndromes
Schwartz, J. R., Ma, J., Lamprecht, T., Walsh, M., Wang, S., Bryant, V., Song, G., Wu, G., Easton, J., Kesserwan, C., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01590-5 · Cited by 210
Genetic predisposition to hematologic malignancies: management and surveillance
Godley, L. A., & Shimamura, A. (2017) · Blood · doi:10.1182/blood-2017-02-735290 · Cited by 190
Role of Casein Kinase 1A1 in the Biology and Targeted Therapy of del(5q) MDS
Schneider, R. K., Ademà, V., Heckl, D., Järås, M., Mallo, M., Lord, A. M., Chu, L. P., McConkey, M. E., Kramann, R., Mullally, A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.08.001 · Cited by 188
Della Porta, M. G., Alessandrino, E. P., Bacigalupo, A., van Lint, M. T., Malcovati, L., Pascutto, C., Falda, M., Bernardi, M., Onida, F., Guidi, S., et al. (2014) · Blood · doi:10.1182/blood-2013-12-542720 · Cited by 179
Self-citationTime-dependent changes in mortality and transformation risk in MDS
Pfeilstöcker, M., Tuechler, H., Sanz, G., Schanz, J., Garcia-Manero, G., Solé, F., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., et al. (2016) · Blood · doi:10.1182/blood-2016-02-700054 · Cited by 179
Self-citationTargeted sequencing identifies patients with preclinical MDS at high risk of disease progression
Cargo, C. A., Rowbotham, N., Evans, P. A., Barrans, S. L., Bowen, D. T., Crouch, S., & Jack, A. S. (2015) · Blood · doi:10.1182/blood-2015-08-663237 · Cited by 178
Shiozawa, Y., Malcovati, L., Gallì, A., Sato-Otsubo, A., Kataoka, K., Sato, Y., Watatani, Y., Suzuki, H., Yoshizato, T., Yoshida, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06063-x · Cited by 176
Self-citationGenetics of progression from MDS to secondary leukemia
Menssen, A. J., & Walter, M. J. (2020) · Blood · doi:10.1182/blood.2019000942 · Cited by 170
Fenaux, P., Santini, V., Spiriti, M. A. A., Giagounidis, A., Schlag, R., Radinoff, A., Gercheva-Kyuchukova, L., Anagnostopoulos, A., Oliva, E. N., Symeonidis, A., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0118-9 · Cited by 163
Unnikrishnan, A., Papaemmanuil, E., Beck, D., Deshpande, N., Verma, A., Kumari, A., Woll, P. S., Richards, L. A., Knezevic, K., Chandrakanthan, V., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.06.067 · Cited by 144
Stahl, M. F., DeVeaux, M., de Witte, T., Neukirchen, J., Sekeres, M. A., Brunner, A. M., Roboz, G. J., Steensma, D. P., Bhatt, V. R., Platzbecker, U., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018019414 · Cited by 144
Genetic predisposition to MDS: clinical features and clonal evolution
Kennedy, A. L., & Shimamura, A. (2019) · Blood · doi:10.1182/blood-2018-10-844662 · Cited by 133
The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants
Rio‐Machín, A., Vulliamy, T., Hug, N., Walne, A. J., Tawana, K., Cardoso, S. R., Ellison, A., Pontikos, N., Wang, J., Tummala, H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14829-5 · Cited by 130
Mutation Clearance after Transplantation for Myelodysplastic Syndrome
Duncavage, E. J., Jacoby, M. A., Chang, G. S., Miller, C. A., Edwin, N. C., Shao, J., Elliott, K., Robinson, J., Abel, H., Fulton, R. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804714 · Cited by 129
Angelucci, E., Li, J., Greenberg, P., Wu, D., Hou, M., Montaňo Figueroa, E. H., Rodriguez, M. G., Dong, X., Ghosh, J., Izquierdo, M., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m19-0916 · Cited by 120
Myers, K. C., Furutani, E., Weller, E., Siegele, B., Galvin, A., Arsenault, V., Alter, B. P., Boulad, F., Bueso-Ramos, C., Burroughs, L., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30206-6 · Cited by 119
Stein, E. M., Fathi, A. T., Dinardo, C. D., Pollyea, D. A., Roboz, G. J., Collins, R. H., Sekeres, M. A., Stone, R. M., Attar, E. C., Frattini, M. G., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30284-4 · Cited by 115
Clinical Relevance of Anemia and Transfusion Iron Overload in Myelodysplastic Syndromes
Cazzola, M., Porta, M. G. D., & Malcovati, L. (2008) · Hematology · doi:10.1182/asheducation-2008.1.166 · Cited by 114
Self-citationCoordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q− syndrome
Kumar, M. S., Narla, A., Nonami, A., Mullally, A., Dimitrova, N., Ball, B., McAuley, J. R., Poveromo, L., Kutok, J. L., Galili, N., et al. (2011) · Blood · doi:10.1182/blood-2010-12-324715 · Cited by 110
Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA)
Brown, A. L., Hahn, C. N., & Scott, H. S. (2020) · Blood · doi:10.1182/blood.2019000937 · Cited by 106
Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome
Bono, E. B., McLornan, D. P., Travaglino, E., Gandhi, S., Gallì, A., Khan, A. A., Kulasekararaj, A. G., Boveri, E., Raj, K. K., Elena, C., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0457-1 · Cited by 98
Self-citationA variant erythroferrone disrupts iron homeostasis in SF3B1 -mutated myelodysplastic syndrome
Bondu, S., Alary, A.-S., Lefèvre, C., Houy, A., Jung, G., Lefebvre, T., Rombaut, D., Boussaid, I., Bousta, A., Guillonneau, F., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav5467 · Cited by 85
Pronk, E., & Raaijmakers, M. H. G. P. (2019) · Blood · doi:10.1182/blood-2018-10-844639 · Cited by 85
SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells
Blanco, T. M., Dimitriou, M., Woll, P. S., Karimi, M., Elvarsdóttir, E. M., Conte, S., Tobiasson, M., Jansson, M., Douagi, I., Moarii, M., et al. (2017) · Blood · doi:10.1182/blood-2017-03-776070 · Cited by 81
Stanworth, S. J., Killick, S. B., McQuilten, Z., Καρακάντζα, Μ., Weinkove, R., Smethurst, H., Pankhurst, L. A., Hodge, R. L., Hopkins, V., Thomas, H., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16347 · Cited by 74
Induction of p53 and up-regulation of the p53 pathway in the human 5q− syndrome
Pellagatti, A., Marafioti, T., Paterson, J. C., Barlow, J. L., Drynan, L. F., Giagounidis, A. A. N., Pileri, S. A., Cazzola, M., McKenzie, A. N. J., Wainscoat, J. S., et al. (2010) · Blood · doi:10.1182/blood-2009-12-259705 · Cited by 68
Self-citationDalton, W. B., Helmenstine, E., Pieterse, L., Li, B., Gocke, C. D., Donaldson, J. M., Xiao, Z., Gondek, L. P., Ghiaur, G., Gojo, I., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001127 · Cited by 68
Gondek, L. P., & DeZern, A. E. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30211-x · Cited by 63
Zeidan, A. M., Stahl, M. F., Sekeres, M. A., Steensma, D. P., Komrokji, R. S., & Gore, S. D. (2017) · Cancer · doi:10.1002/cncr.30903 · Cited by 54
Ribezzo, F., Snoeren, I. A. M., Ziegler, S., Stoelben, J., Olofsen, P. A., Henic, A., Ferreira, M. V., Chen, S., Stalmann, U. S. A., Buesche, G., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0350-3 · Cited by 51
Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens
Saber, W., & Horowitz, M. M. (2016) · Hematology · doi:10.1182/asheducation-2016.1.478 · Cited by 50
Starkman, R., Alibhai, S. M. H., Wells, R. A., Geddes, M. N., Zhu, N. Y., Keating, M., Leber, B. F., Chodirker, L., Sabloff, M., Christou, G., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0666-7 · Cited by 44
Martinez-Høyer, S., Deng, Y., Parker, J., Jiang, J., Mo, A., Docking, T. R., Gharaee, N., Li, J., Umlandt, P., Fuller, M., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0497-9 · Cited by 42
Integrating patient-centered factors in the risk assessment of MDS
Buckstein, R. J. (2019) · Hematology · doi:10.1182/hematology.2019000041 · Cited by 21
Impact of lenalidomide use among non‐transfusion dependent patients with myelodysplastic syndromes
Brunner, A. M., Weng, S., Cronin, A. M., Fathi, A. T., Habib, A. R., Stone, R. M., Graubert, T., Steensma, D. P., & Abel, G. A. (2018) · American Journal of Hematology · doi:10.1002/ajh.25166 · Cited by 11
Cited by
Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
Bernard, E., Tuechler, H., Greenberg, P. L., Hasserjian, R. P., Arango Ossa, J. E., Nannya, Y., Devlin, S. M., Creignou, M., Pinel, P., Monnier, L., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2200008 · Cited by 867
Self-citationEvolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue, C., Yao, Q., Gu, X., Shi, Q., Yuan, X., Chu, Q., Bao, Z., Lu, J., & Li, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01468-7 · Cited by 699
Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
Tian, Z., Liu, M., Zhang, Y., & Wang, X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01084-4 · Cited by 282
Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS
Trowbridge, J. J., & Starczynowski, D. T. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201544 · Cited by 189
High-Throughput CRISPR Screening in Hematological Neoplasms
Ancos-Pintado, R., Bragado-García, I., Morales, M. L., García-Vicente, R., Arroyo-Barea, A., Rodríguez-García, A., Martínez-López, J., Linares, M., & Hernández-Sánchez, M. (2022) · Cancers · doi:10.3390/cancers14153612 · Cited by 15
Metadata
- Authors
- Cazzola, M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-10
- Volume
- 383
- Issue
- 14
- Pages
- 1358-1374
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4252225072
- Cited by
- 491
- References
- 99
- FWCI
- 37.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.